Almirall H1 2025 Results: Strong Sales Growth and Reiterated Guidance

Almirall has reported a 12.7% increase in total net sales to €560.5m in H1 2025, driven by its dermatology business in Europe. Ebglyss, a treatment for atopic dermatitis, generated €45m in net sales, while Ilumetri, a psoriasis treatment, achieved €58m in Q2 sales. The company reiterates its full-year guidance for 2025, expecting double-digit net sales growth and EBITDA between €220m and €240m.

Almirall has reported a 12.7% increase in total net sales to €560.5m in H1 2025, driven by its dermatology business in Europe. The company's treatment for atopic dermatitis, Ebglyss, generated €45m in net sales, while Ilumetri, a psoriasis treatment, achieved €58m in Q2 sales. Almirall reiterated its full-year guidance for 2025, expecting double-digit net sales growth and EBITDA between €220m and €240m [1].

The company's strong performance in the first half of 2025 is a testament to the effectiveness of its dermatology portfolio, which continues to grow in popularity and efficacy. Ebglyss and Ilumetri have shown significant potential in the market, contributing substantially to Almirall's overall revenue.

Looking ahead, Almirall remains committed to its strategy of investing in innovation and expanding its portfolio of dermatology treatments. The company's partnership with other life science organizations and its focus on AI-driven drug discovery and development are expected to further bolster its growth prospects [2].

References:

[1] Current Partnering. (2025). CP Scorecard 2025. Retrieved from https://www.currentpartnering.com/insight/
[2] AstraZeneca. (2025). AstraZeneca and CSPC Pharmaceutical Group Enter Strategic Research Collaboration. Retrieved from https://www.astrazeneca.com/